Short summary: Amycretin is an investigational medicine from Novo Nordisk that targets both GLP-1 and amylin pathways. Early studies are interesting, but amycretin is not an approved treatment and long-term safety, outcomes, dosing, access, and place in care remain unsettled.
Key takeaways
- Amycretin is designed to activate GLP-1 and amylin receptors in one medicine.
- Early trials reported substantial weight loss, but the studies were relatively small and mostly short.
- Gastrointestinal side effects such as nausea, vomiting, and reduced appetite were common in early studies.
- Amycretin is investigational. It is not a treatment to seek outside regulated clinical trials.
What is amycretin?
Amycretin is a dual GLP-1 and amylin receptor agonist being studied for obesity and type 2 diabetes. GLP-1 medicines can increase glucose-dependent insulin release, reduce glucagon, slow stomach emptying, and reduce appetite. Amylin is another hormone involved in appetite, stomach emptying, and post-meal glucose regulation.
The idea is that targeting both pathways might produce stronger metabolic effects than targeting GLP-1 alone. That idea still needs confirmation in larger, longer trials that measure not only weight and HbA1c, but also safety, tolerability, cardiovascular outcomes, durability, and quality of life.
What early studies reported
In the Lancet phase 1 trial, participants receiving the highest tested oral amycretin dose had a mean body weight reduction of approximately 13 percent after 12 weeks, compared with about 1 percent with placebo. Lower doses showed smaller reductions.
In a dose-escalation arm of a phase 1b/2a study of once-weekly subcutaneous amycretin, the 60 mg group had an estimated mean body weight change of about 24 percent at week 36, compared with about 1 percent with placebo. Other tested dose groups had smaller reductions over different treatment durations. These were early studies in selected participants, not long-term outcome trials.
These numbers should be read carefully. Early-phase trials are designed mainly to study safety, tolerability, dosing, and early biological effects. They do not prove how a medicine will perform across broader populations, over years, or against existing approved treatments.
What about type 2 diabetes?
Novo Nordisk has reported phase 2 results in people with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. The company reported dose-dependent HbA1c reductions and weight loss over up to 36 weeks. Company releases are useful for tracking development, but they are not the same as full peer-reviewed trial reports. As of May 2026, full peer-reviewed phase 2 data in type 2 diabetes had not been published.
For now, patients should not view amycretin as an available diabetes option. Approved diabetes and obesity medicines already have clearer labeling, known dosing, and more established safety information.
Side effects and unanswered questions
Gastrointestinal symptoms were common in early amycretin studies, similar to what is often seen with incretin-based therapies. ACC’s summary of the Lancet studies noted nausea, vomiting, and decreased appetite among common events, with most reported events mild or moderate in the early trials.
Key unanswered questions remain: how well people tolerate amycretin over longer periods, how much discontinuation occurs in routine care, whether benefits persist, how it compares head-to-head with existing GLP-1 and dual incretin medicines, whether it improves cardiovascular or kidney outcomes, and how access and cost will be handled if approved.
What readers should do with this news
Amycretin is worth watching, not chasing. If you are living with type 2 diabetes, obesity, kidney disease, heart disease, or medication side effects, discuss currently approved options with your clinician. Avoid compounded or online products marketed as amycretin or as research chemicals.
Useful background before following amycretin news includes our guides to CagriSema, diabetes medications, and GLP-1 side effect management.
Practical takeaway
Amycretin is promising enough to follow, but too early to treat as proven. Wait for larger phase 3 data, peer-reviewed type 2 diabetes results, regulatory decisions, and clear safety information before drawing patient-care conclusions.
Sources
- The Lancet: oral amycretin first-in-human phase 1 trial
- PubMed: subcutaneous amycretin phase 1b/2a study
- American College of Cardiology: summary of oral and subcutaneous amycretin studies
- Novo Nordisk via Nasdaq: phase 2 amycretin results in type 2 diabetes
- Novo Nordisk via Nasdaq: amycretin phase 3 weight management development
Content date: May 2026. Amycretin evidence is changing quickly, so development status and peer-reviewed phase 2 publication status should be rechecked during future updates.
Editorial review note: reviewed for medical accuracy, source consistency, investigational-drug caveats, promotional-language control, and patient-safety framing before publication.